Literature DB >> 25515373

Staphylococcus aureus-Related Diabetic Osteomyelitis: Medical or Surgical Management? A French and Spanish Retrospective Cohort.

Olivier Lesens1, Françoise Desbiez2, Clément Theïs3, Tristant Ferry4, Maryse Bensalem5, Henri Laurichesse3, Igor Tauveron6, Jean Beytout3, Javier Aragón Sánchez7.   

Abstract

Staphylococcus aureus is the main cause of diabetic foot osteomyelitis (DFO) and can be treated medically or by surgery. We investigated the outcome of consecutive patients with a diagnosis of S aureus DFO retrospectively in 4 hospitals according to the type of management, medical (including debridement at bedside) or surgical. The outcome was classified as either favorable or failure (relapse, impaired wound healing, or amputation). Seventy-four patients with S aureus DFO, including 26 with methicillin-resistant S aureus, were included with a mean duration of follow-up of 21 ± 1 months. As part of the initial treatment, 47% underwent bone surgery followed with a short course of antibiotic. Others were treated with antibiotic therapy alone with bedside debridement. The outcome was favorable for 84% of these patients, with similar rates in the surgical and medical groups (80% vs 87%, P > .05). Patients in the medical group were less frequently hospitalized (49% vs 94%, P < .001) and had a shorter length of hospital stay (17 ± 3 vs 50 ± 12 days, P = .004). Patients in the surgery group received a shorter course of antibiotic therapy (10 ± 2 vs 11 ± 1 weeks, P = .001) with fewer side effects (9% vs 33%, P = .01). The type of management was not associated with subsequent new episode of noncontiguous DFO, which developed in 32% of cases. In conclusion, except significant differences in duration of hospitalization and antibiotic therapy, medical and surgical management of S aureus DFO had similar outcomes with a cure rate >80%.
© The Author(s) 2014.

Entities:  

Keywords:  Staphylococcus aureus; amputation; diabetic foot; osteomyelitis

Mesh:

Substances:

Year:  2014        PMID: 25515373     DOI: 10.1177/1534734614559931

Source DB:  PubMed          Journal:  Int J Low Extrem Wounds        ISSN: 1534-7346            Impact factor:   2.057


  10 in total

Review 1.  Diabetic Foot Infections: Update on Management.

Authors:  Maria Nikoloudi; Ioanna Eleftheriadou; Anastasios Tentolouris; Ourania A Kosta; Nikolaos Tentolouris
Journal:  Curr Infect Dis Rep       Date:  2018-08-01       Impact factor: 3.725

2.  Meta-Analysis: Outcomes of Surgical and Medical Management of Diabetic Foot Osteomyelitis.

Authors:  David H Truong; Roger Bedimo; Matthew Malone; Dane K Wukich; Orhan K Oz; Amanda L Killeen; Lawrence A Lavery
Journal:  Open Forum Infect Dis       Date:  2022-08-09       Impact factor: 4.423

3.  Erythrocyte sedimentation rate and C-reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis.

Authors:  Suzanne Av van Asten; Daniel C Jupiter; Moez Mithani; Javier La Fontaine; Kathryn E Davis; Lawrence A Lavery
Journal:  Int Wound J       Date:  2016-03-08       Impact factor: 3.315

Review 4.  Staphylococcus aureus Toxins and Diabetic Foot Ulcers: Role in Pathogenesis and Interest in Diagnosis.

Authors:  Catherine Dunyach-Remy; Christelle Ngba Essebe; Albert Sotto; Jean-Philippe Lavigne
Journal:  Toxins (Basel)       Date:  2016-07-07       Impact factor: 4.546

5.  Treatment of Charcot Neuroarthropathy and osteomyelitis of the same foot: a retrospective cohort study.

Authors:  Martin Berli; Lazaros Vlachopoulos; Sabra Leupi; Thomas Böni; Charlotte Baltin
Journal:  BMC Musculoskelet Disord       Date:  2017-11-16       Impact factor: 2.362

6.  Decrease of Staphylococcus aureus Virulence by Helcococcus kunzii in a Caenorhabditis elegans Model.

Authors:  Christelle Ngba Essebe; Orane Visvikis; Marguerite Fines-Guyon; Anne Vergne; Vincent Cattoir; Alain Lecoustumier; Emmanuel Lemichez; Albert Sotto; Jean-Philippe Lavigne; Catherine Dunyach-Remy
Journal:  Front Cell Infect Microbiol       Date:  2017-03-16       Impact factor: 5.293

Review 7.  Optimal management of diabetic foot osteomyelitis: challenges and solutions.

Authors:  José Luis Lázaro Martínez; Yolanda García Álvarez; Aroa Tardáguila-García; Esther García Morales
Journal:  Diabetes Metab Syndr Obes       Date:  2019-06-21       Impact factor: 3.168

8.  Long-Term Complications after Surgical or Medical Treatment of Predominantly Forefoot Diabetic Foot Osteomyelitis: 1 Year Follow Up.

Authors:  Aroa Tardáguila-García; Yolanda García-Álvarez; Esther García-Morales; Mateo López-Moral; Irene Sanz-Corbalán; José Luis Lázaro-Martínez
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

Review 9.  Molecular Imaging of Diabetic Foot Infections: New Tools for Old Questions.

Authors:  Camilo A Ruiz-Bedoya; Oren Gordon; Filipa Mota; Sudhanshu Abhishek; Elizabeth W Tucker; Alvaro A Ordonez; Sanjay K Jain
Journal:  Int J Mol Sci       Date:  2019-11-28       Impact factor: 5.923

10.  Possible Advantages of S53P4 Bioactive Glass in the Treatment of Septic Osteoarthritis of the First Metatarsophalangeal Joint in the Diabetic Foot.

Authors:  Matevž Kastrin; Vilma Urbančič Rovan; Igor Frangež
Journal:  J Clin Med       Date:  2021-03-15       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.